Literature DB >> 23791986

The role of IL-15 in gastrointestinal diseases: a bridge between innate and adaptive immune response.

Danilo Pagliari1, Rossella Cianci, Simona Frosali, Raffaele Landolfi, Giovanni Cammarota, Estelle E Newton, Franco Pandolfi.   

Abstract

IL-15 is a member of the IL-2 family of cytokines whose signaling pathways are a bridge between innate and adaptive immune response. IL-15 is part of the intestinal mucosal barrier, and functions to modulate gut homeostasis. IL-15 has pivotal roles in the control of development, proliferation and survival of both innate and adaptive immune cells. IL-15 becomes up-regulated in the inflamed tissue of intestinal inflammatory disease, such as IBD, Celiac Disease and related complications. Indeed, several studies have reported that IL-15 may participate to the pathogenesis of these diseases. Furthermore, although IL-15 seems to be responsible for inflammation and autoimmunity, it also may increase the immune response against cancer. For these reasons, we decided to study the intestinal mucosa as an 'immunological niche', in which immune response, inflammation and local homeostasis are modulated. Understanding the role of the IL-15/IL-15R system will provide a scientific basis for the development of new approaches that use IL-15 for immunotherapy of autoimmune diseases and malignancies. Indeed, a better understanding of the complexity of the mucosal immune system will contribute to the general understanding of immuno-pathology, which could lead to new therapeutical tools for widespread immuno-mediated diseases.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Celiac Disease; Colorectal cancer; IL-15; Immunological niche; Inflammatory Bowel Diseases

Mesh:

Substances:

Year:  2013        PMID: 23791986     DOI: 10.1016/j.cytogfr.2013.05.004

Source DB:  PubMed          Journal:  Cytokine Growth Factor Rev        ISSN: 1359-6101            Impact factor:   7.638


  27 in total

1.  Gliadin-dependent cytokine production in a bidimensional cellular model of celiac intestinal mucosa.

Authors:  Olimpia Vincentini; Francesca Maialetti; Elena Gonnelli; Marco Silano
Journal:  Clin Exp Med       Date:  2014-12-02       Impact factor: 3.984

2.  IL-15 temporally reorients IL-10 biased B-1a cells toward IL-12 expression.

Authors:  Amlan Kanti Ghosh; Debolina Sinha; Subhadeep Mukherjee; Ratna Biswas; Tapas Biswas
Journal:  Cell Mol Immunol       Date:  2015-03-09       Impact factor: 11.530

3.  Discovery and characterization of a novel humanized anti-IL-15 antibody and its relevance for the treatment of refractory celiac disease and eosinophilic esophagitis.

Authors:  Alain P Vicari; Alain M Schoepfer; Bertrand Meresse; Laurence Goffin; Olivier Léger; Soheila Josserand; Nicolas Guégan; Shida Yousefi; Alex Straumann; Nadine Cerf-Bensussan; Hans-Uwe Simon; Yolande Chvatchko
Journal:  MAbs       Date:  2017-06-05       Impact factor: 5.857

4.  Self-reactive, innate-like T cells enhance cytotoxicity and immunosurveillance.

Authors:  Blaire E Barton; Cindy H Chau; William D Figg
Journal:  Trends Cancer       Date:  2022-06-04

Review 5.  Celiac disease: understanding the gluten-free diet.

Authors:  Karla A Bascuñán; María Catalina Vespa; Magdalena Araya
Journal:  Eur J Nutr       Date:  2016-06-22       Impact factor: 5.614

6.  Protective effect of myokine IL-15 against H2O2-mediated oxidative stress in skeletal muscle cells.

Authors:  Fengna Li; Yinghui Li; Yulong Tang; Binbin Lin; Xiangfeng Kong; Oso Abimbola Oladele; Yulong Yin
Journal:  Mol Biol Rep       Date:  2014-08-08       Impact factor: 2.316

Review 7.  JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines.

Authors:  Silvio Danese; Matthew Grisham; Jennifer Hodge; Jean-Baptiste Telliez
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-11-25       Impact factor: 4.052

8.  Effect of Lactobacillus paracasei CNCM I-1572 on symptoms, gut microbiota, short chain fatty acids, and immune activation in patients with irritable bowel syndrome: A pilot randomized clinical trial.

Authors:  Cesare Cremon; Simone Guglielmetti; Giorgio Gargari; Valentina Taverniti; Anna Maria Castellazzi; Chiara Valsecchi; Carlotta Tagliacarne; Walter Fiore; Massimo Bellini; Lorenzo Bertani; Dario Gambaccini; Michele Cicala; Bastianello Germanà; Maurizio Vecchi; Isabella Pagano; Maria Raffaella Barbaro; Lara Bellacosa; Vincenzo Stanghellini; Giovanni Barbara
Journal:  United European Gastroenterol J       Date:  2017-10-08       Impact factor: 4.623

Review 9.  How the Intricate Interaction among Toll-Like Receptors, Microbiota, and Intestinal Immunity Can Influence Gastrointestinal Pathology.

Authors:  Simona Frosali; Danilo Pagliari; Giovanni Gambassi; Raffaele Landolfi; Franco Pandolfi; Rossella Cianci
Journal:  J Immunol Res       Date:  2015-05-18       Impact factor: 4.818

10.  Fine tuning of the DNAM-1/TIGIT/ligand axis in mucosal T cells and its dysregulation in pediatric inflammatory bowel diseases (IBD).

Authors:  S Battella; S Oliva; L Franchitti; R La Scaleia; A Soriani; S Isoldi; C Capuano; C Pighi; S Morrone; R Galandrini; A Santoni; G Palmieri
Journal:  Mucosal Immunol       Date:  2019-10-03       Impact factor: 7.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.